Kyinno is a preclinical contract research organization (CRO) specializing in customized services for drug discovery, including in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and innovative antibody discovery. With a robust asset base of over 3,000 engineered cell lines, advanced antibody discovery mouse models, and a proprietary AI-driven antibody development platform, Kyinno supports researchers and pharmaceutical companies by facilitating critical advances in biomedical research and drug development. The organization's extensive offerings include engineered cell lines for various applications, drug-resistant cell lines, and specialized kinase cell lines, among others, tailored to meet the unique needs of its clients.

Kyinno Biotechnology (康源博创)

Kyinno Biotechnology (康源博创)